VTVT | vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study – Stocks News Feed

Share this Stock Information HIGH POINT, N.C., Nov.04, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.(Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease (AD) in people with type 2 diabetes (NCT03980730).The data demonstrate that the patients… Read More […]

VTVT | Dementia with Diabetes Pipeline Insight Report, 2020 – Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type

Dublin, Nov.04, 2020 (GLOBE NEWSWIRE) — The “Dementia with Diabetes – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.The “Dementia with Diabetes – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Dementia with Diabetes pipeline landscape.It covers the pipeline drug profiles, including clinical and […]